Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss Data - What's Changed

Simply Wall St.2025-12-25

In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2594282034?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2025-12-25 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594282034","market":"us","top_or_hot":-1,"title":"Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss Data - What's Changed","media":"Simply Wall St.","content":"<div>\n<p>In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss Data - What's Changed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWave Life Sciences (WVE) Is Up 11.7% After Early WVE-007 Fat-Loss Data - What's Changed\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 10:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WVE","symbol_name":"Wave Life Sciences Pte. Ltd","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los","article_id":"2594282034","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-wve/wave-life-sciences/news/wave-life-sciences-wve-is-up-117-after-early-wve-007-fat-los","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594282034","pubTimestamp":1766630739,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in lean mass after a single 240 mg dose in metabolic disease patients.\nBecause WVE-007’s early results suggest simultaneous fat loss and lean mass preservation, it may address an important limitation of many existing obesity treatments.\nNext, we’ll explore how this early WVE-007 efficacy and safety...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"WVE":"Wave Life Sciences Pte. Ltd","BK4007":"制药"},"translate_title":"Wave Life Sciences(WVE)在早期WVE-007减脂数据公布后上涨11.7%-发生了什么变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":1.5},"content_text":"In December 2025, Wave Life Sciences reported interim Phase 1 INLIGHT data for its investigational siRNA therapy WVE-007, showing meaningful reductions in visceral and total body fat and increases in lean mass after a single 240 mg dose in metabolic disease patients. Because WVE-007’s early results suggest simultaneous fat loss and lean mass preservation, it may address an important limitation of many existing obesity treatments. Next, we’ll explore how this early WVE-007 efficacy and safety profile could influence Wave Life Sciences’ broader investment narrative. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Wave Life Sciences Investment Narrative RecapTo own Wave Life Sciences, you basically have to believe its RNA platform can turn early clinical wins into approved products before the cash runs thin. The WVE-007 INLIGHT data strengthens the near term obesity catalyst, but also raises the stakes on execution and funding needs after the recent US$350.0 million equity raise, in a business that is still unprofitable and reliant on a few lead programs. The December 2025 follow on equity offering, totaling about US$350.0 million, is especially relevant here because it extends Wave’s runway just as WVE-007 moves from promising Phase 1 data toward larger, more expensive trials. That extra capital may help the company progress obesity and AATD programs toward their late 2025 and early 2026 readouts, while partially offsetting pressure from rising R&D spend and prior revenue declines. Yet, despite the encouraging WVE 007 data, investors should be aware of the risk that continued net losses and reliance on a few key trials could... Read the full narrative on Wave Life Sciences (it's free!)Wave Life Sciences' narrative projects $177.5 million revenue and $41.2 million earnings by 2028.Uncover how Wave Life Sciences' forecasts yield a $31.60 fair value, a 73% upside to its current price.Exploring Other PerspectivesWVE 1-Year Stock Price Chart Three members of the Simply Wall St Community value Wave anywhere from US$31.6 to US$1,469.79, underscoring just how far opinions can stretch. You may want to weigh those views against the fact that the company remains unprofitable with widening losses and depends heavily on a small set of binary clinical catalysts.Explore 3 other fair value estimates on Wave Life Sciences - why the stock might be worth just $31.60!Build Your Own Wave Life Sciences NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Wave Life Sciences research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.Our free Wave Life Sciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Wave Life Sciences' overall financial health at a glance.Ready For A Different Approach?These stocks are moving-our analysis flagged them today. Act fast before the price catches up:Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.Uncover the next big thing with financially sound penny stocks that balance risk and reward.These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechValuation is complex, but we're here to simplify it.Discover if Wave Life Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594282034","isCrawlerRequest":true}